Examination of priorities for therapeutic drug utilization review

M. Diehl, D. Lago, F. Ahern, M. A. Smyer, S. Hermanson, V. Rabatin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Therapeutic Drug Utilization Review (DUR) is an important component of state-level pharmaceutical assistance programs like Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE). Two separate studies were conducted to examine reviewers' priorities for screening drug- drug interactions within PACE; specific emphasis was placed on screening potentially adverse drug interactions. A group of 15 pharmacists and physicians serving on PACE DUR committees were asked to provide elderly- specific ratings on the 'clinical significance' and the 'need for action' for 122 specified drug interactions well-documented in the clinical pharmacy literature. In Study 1, reviewers were asked to provide ratings for each type of drug interaction shown in a one-page clinical description. In Study 2, reviewers were asked to evaluate a subset of the previously rated drug interactions, as they appeared in a set of selected PACE cardholders' drug use profiles. In both studies, considerable variability was found among DUR members' evaluations for both rating dimensions. Consensus was achieved for only a limited number of interactions. Implications of the findings for DUR within state-level pharmaceutical programs and the general issue of screening for adverse drug interactions in the elderly are discussed.

Original languageEnglish (US)
Pages (from-to)65-85
Number of pages21
JournalJournal of Geriatric Drug Therapy
Volume6
Issue number2
StatePublished - Dec 1 1991

Fingerprint

Drug Utilization Review
Drug Interactions
Contracts
Pharmaceutical Preparations
Therapeutics
Preclinical Drug Evaluations
Advisory Committees
Pharmacists
Physicians

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this

Diehl, M., Lago, D., Ahern, F., Smyer, M. A., Hermanson, S., & Rabatin, V. (1991). Examination of priorities for therapeutic drug utilization review. Journal of Geriatric Drug Therapy, 6(2), 65-85.
Diehl, M. ; Lago, D. ; Ahern, F. ; Smyer, M. A. ; Hermanson, S. ; Rabatin, V. / Examination of priorities for therapeutic drug utilization review. In: Journal of Geriatric Drug Therapy. 1991 ; Vol. 6, No. 2. pp. 65-85.
@article{d2d44b0fb165427e96c8e150c2cbfe9c,
title = "Examination of priorities for therapeutic drug utilization review",
abstract = "Therapeutic Drug Utilization Review (DUR) is an important component of state-level pharmaceutical assistance programs like Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE). Two separate studies were conducted to examine reviewers' priorities for screening drug- drug interactions within PACE; specific emphasis was placed on screening potentially adverse drug interactions. A group of 15 pharmacists and physicians serving on PACE DUR committees were asked to provide elderly- specific ratings on the 'clinical significance' and the 'need for action' for 122 specified drug interactions well-documented in the clinical pharmacy literature. In Study 1, reviewers were asked to provide ratings for each type of drug interaction shown in a one-page clinical description. In Study 2, reviewers were asked to evaluate a subset of the previously rated drug interactions, as they appeared in a set of selected PACE cardholders' drug use profiles. In both studies, considerable variability was found among DUR members' evaluations for both rating dimensions. Consensus was achieved for only a limited number of interactions. Implications of the findings for DUR within state-level pharmaceutical programs and the general issue of screening for adverse drug interactions in the elderly are discussed.",
author = "M. Diehl and D. Lago and F. Ahern and Smyer, {M. A.} and S. Hermanson and V. Rabatin",
year = "1991",
month = "12",
day = "1",
language = "English (US)",
volume = "6",
pages = "65--85",
journal = "Journal of Geriatric Drug Therapy",
issn = "8756-4629",
publisher = "Haworth Press Inc.",
number = "2",

}

Diehl, M, Lago, D, Ahern, F, Smyer, MA, Hermanson, S & Rabatin, V 1991, 'Examination of priorities for therapeutic drug utilization review', Journal of Geriatric Drug Therapy, vol. 6, no. 2, pp. 65-85.

Examination of priorities for therapeutic drug utilization review. / Diehl, M.; Lago, D.; Ahern, F.; Smyer, M. A.; Hermanson, S.; Rabatin, V.

In: Journal of Geriatric Drug Therapy, Vol. 6, No. 2, 01.12.1991, p. 65-85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Examination of priorities for therapeutic drug utilization review

AU - Diehl, M.

AU - Lago, D.

AU - Ahern, F.

AU - Smyer, M. A.

AU - Hermanson, S.

AU - Rabatin, V.

PY - 1991/12/1

Y1 - 1991/12/1

N2 - Therapeutic Drug Utilization Review (DUR) is an important component of state-level pharmaceutical assistance programs like Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE). Two separate studies were conducted to examine reviewers' priorities for screening drug- drug interactions within PACE; specific emphasis was placed on screening potentially adverse drug interactions. A group of 15 pharmacists and physicians serving on PACE DUR committees were asked to provide elderly- specific ratings on the 'clinical significance' and the 'need for action' for 122 specified drug interactions well-documented in the clinical pharmacy literature. In Study 1, reviewers were asked to provide ratings for each type of drug interaction shown in a one-page clinical description. In Study 2, reviewers were asked to evaluate a subset of the previously rated drug interactions, as they appeared in a set of selected PACE cardholders' drug use profiles. In both studies, considerable variability was found among DUR members' evaluations for both rating dimensions. Consensus was achieved for only a limited number of interactions. Implications of the findings for DUR within state-level pharmaceutical programs and the general issue of screening for adverse drug interactions in the elderly are discussed.

AB - Therapeutic Drug Utilization Review (DUR) is an important component of state-level pharmaceutical assistance programs like Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE). Two separate studies were conducted to examine reviewers' priorities for screening drug- drug interactions within PACE; specific emphasis was placed on screening potentially adverse drug interactions. A group of 15 pharmacists and physicians serving on PACE DUR committees were asked to provide elderly- specific ratings on the 'clinical significance' and the 'need for action' for 122 specified drug interactions well-documented in the clinical pharmacy literature. In Study 1, reviewers were asked to provide ratings for each type of drug interaction shown in a one-page clinical description. In Study 2, reviewers were asked to evaluate a subset of the previously rated drug interactions, as they appeared in a set of selected PACE cardholders' drug use profiles. In both studies, considerable variability was found among DUR members' evaluations for both rating dimensions. Consensus was achieved for only a limited number of interactions. Implications of the findings for DUR within state-level pharmaceutical programs and the general issue of screening for adverse drug interactions in the elderly are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026346469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026346469&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026346469

VL - 6

SP - 65

EP - 85

JO - Journal of Geriatric Drug Therapy

JF - Journal of Geriatric Drug Therapy

SN - 8756-4629

IS - 2

ER -

Diehl M, Lago D, Ahern F, Smyer MA, Hermanson S, Rabatin V. Examination of priorities for therapeutic drug utilization review. Journal of Geriatric Drug Therapy. 1991 Dec 1;6(2):65-85.